Celgene's Revlimid improves survival in blood cancer patients

July 11 Thu Jul 11, 2013 7:47am EDT

July 11 (Reuters) - Celgene Corp said a late-stage trial of its cancer drug Revlimid met the main goal of improving survival in blood cancer patients.

The drug was tested in patients with newly diagnosed multiple myeloma, and showed a statistically significant improvement in survival, without the cancer worsening.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.